Hummingbird Collaborates with Novogene to Expand Precision Therapy Testing for NRG1-Fusion Driven Cancers in China

 Hummingbird Collaborates with Novogene to Expand Precision Therapy Testing for NRG1-Fusion Driven Cancers in China

Hummingbird Collaborates with Novogene to Expand Precision Therapy Testing for NRG1-Fusion Driven Cancers in China

Shots:

  • The partnership will utilize Novogene’s molecular diagnostics capabilities to expand patient identification by NGS in China for supporting the development of Hummingbird’s HMBD-001 which is expected to enter P-I study in 2021 to treat NRG1-fusion driven cancers
  • The partnership focuses on validation and expansion of clinical-grade testing for NRG1 fusions in patient populations with selected solid tumors
  • The pre-clinical studies showed that the therapy potently inhibits the formation of heterodimers, blocking the activation of signaling pathway and prevents tumor growth

Click here to­ read full press release/ article | Ref: PR Newswire | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post